Improved oral delivery of paclitaxel following administration in nanoemulsion formulations

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 3215-3221

  Tiwari, Sandip B ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Hydrophobic Drugs; Nanoemulsions; Oral Absorption; P Glycoprotein; Paclitaxel

Indexed keywords

BIOAVAILABILITY; NANOEMULSIONS; ORAL DRUG DELIVERY; PACLITAXEL; SONICATION;

BIOLOGICAL ORGANS; DRUG PRODUCTS; EMULSIONS; HYDROPHOBICITY; PARTICLE SIZE ANALYSIS; PHARMACOKINETICS; SUBSTRATES;

NANOSTRUCTURED MATERIALS;

ANTINEOPLASTIC AGENT; DRUG CARRIER; EXCIPIENT; NANOMATERIAL; PACLITAXEL;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DRUG FORMULATION; EMULSION; EVALUATION; FEMALE; METABOLIC CLEARANCE RATE; METHODOLOGY; MOUSE; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; EXCIPIENTS; FEMALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; ORGAN SPECIFICITY; PACLITAXEL; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 33750047487     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.440     Document Type: Conference Paper

References (28)

1. W. N. Charman, J. Pharm. Sci. 89, 967 (2000).
2. C. W. Pouton, Eur. J. Pharm. Sci. 11, Suppl 2, S93 (2000).
3. R. P. Bagwe, J. R. Kanicky, B. J. Palla, P. K. Patanjali, and D. O. Shah, Crit. Rev. Ther. Drug Carrier Syst. 18, 77 (2001).
4. K. M. Wasan, Drug Dev. Ind. Pharm. 27, 267 (2001).
5. N. Gursoy, J. S. Garrigue, A. Razafindratsita, G. Lambert, and S. Benita, J. Pharm. Sci. 92, 2411 (2003).
6. T. Gershanik and S. Benita, Eur. J. Pharm. Biopharm. 50, 179 (2000).
7. C. W. Pouton, Adv. Drug Deliv. Rev. 25, 47 (1997).
8. S. M. Khoo, A. J. Humberstone, J. H. Porter, G. A. Edwards, and W. N. Charman, Int. J. Pharm. 167, 155 (1998).
9. R. N. Gursoy and S. Benita, Biomed. Pharmacother. 58, 173 (2004).
10. F. G. Poelma, R. Breas, J. J. Tukker, and D. J. Crommelin, J. Pharm. Pharmacol. 43, 317 (1991).
11. J.-L. Salager, Pharmaceutical Emulsions and Suspensions, edited by F. Nielloud and G. Marti-Mestres, Marcel Dekker, New York (2000), p. 19.
12. J. Lee, S. C. Lee, G. Acharya, C. J. Chang, and K. Park, Pharm. Res. 20, 1022 (2003).
13. A. E. Mathew, M. R. Mejillano, J. P. Nath, R. H. Himes, and V. J. Stella, J. Med. Chem. 35, 145 (1992).
14. R. M. Straubinger, A. Sharma, M. Murray, and E. Mayhew, J. Natl. Cancer Inst. Monogr. 69 (1993).
15. A. K. Singla, A. Garg, and D. Aggarwal, Int. J. Pharm. 235, 179 (2002).
16. M. M. Malingre, J. H. Beijnen, and J. H. Schellens, Invest. New Drugs 19, 155 (2001).
17. H. A. Bardelmeijer, O. van Tellingen, J. H. Schellens, and J. H. Beijnen, Invest. New Drugs 18, 231 (2000).
18. M. M. Malingre, J. H. Beijnen, H. Rosing, F. J. Koopman, O. van Tellingen, K. Duchin, W. W. Ten Bokkel Huinink, M. Swart, J. Lieverst, and J. H. Schellens, Cancer Chemother. Pharmacol. 47, 347 (2001).
19. P. Gao, B. D. Rush, W. P. Pfund, T. Huang, J. M. Bauer, W. Morozowich, M. S. Kuo, and M. J. Hageman, J. Pharm. Sci. 92, 2386 (2003).
20. R. Haskell, www.banyu-zaidan.or.jp/symp/soyaku/haskell.pdf, date accessed (2005).
21. C. Gaysorn, R. T. Lyons, M. V. Patel, and S. L. Hem, J. Pharm. Sci. 88, 454 (1999).
22. M. P. Piemi, D. Korner, S. Benita, and J. P. Marty, J. Control. Rel. 58, 17 (1999).
23. S. C. Yang and S. Benita, Drug Dev. Res. 50, 476 (2000).
24. T. Uno, T. Kazui, Y. Suzuki, H. Hashimoto, K. Suzuki, and B. A. Muhammad, Lipids 34, 249 (1999).
25. K. Buszello and B. Muller, Pharmaceutical Emulsions and Suspensions, edited by F. Nielloud and G. Marti-Mestres, Marcel Dekker, New York (2000), p. 191.
26. M. Sakai, T. Imai, H. Ohtake, H. Azuma, and M. Otagiri, J. Pharm. Pharmacol. 51, 27 (1999).
27. D. L. Zhao and B. H. Hirst, Digestion 47, 200 (1990).
28. S. Yang, R. N. Gursoy, G. Lambert, and S. Benita, Pharm. Res. 21. 261 (2004).